Researchers published a report in Nature Communications on July 31, 2026, examining India's role as an emerging center for antimicrobial development. The study discusses how antibiotic creation historically remained concentrated in high-income nations. It focuses on the implications of India's growing role for global health and equity of access to life-saving therapies.
Nature Communications received the manuscript on March 3, 2026, and accepted it on July 20, 2026. The paper was assigned DOI 10.1038/s41467-026-76186-z upon publication. Authors of the work include Abi Manesh, Kamini Walia, Taslimarif Saiyed, and David L. Paterson.
Authors on the paper represent the Department of Infectious Diseases and the Department of Clinical Microbiology at Christian Medical College in Vellore, India.
Participating organizations also include the Indian Council of Medical Research in New Delhi and the Centre for Cellular and Molecular Platforms in Bangalore and Hyderabad, Telangana. Additional contributors came from ADVANCE-ID at the Saw Swee Hock School of Public Health, National University of Singapore.
Funding statements show the authors received no specific funding for the work. The team also stated that the material had not been presented anywhere else prior to publication.
Dr. David L. Paterson disclosed receiving research grants from Shionogi, Pfizer, Merck, BioVersys, bioMerieux, Johnson & Johnson, and Gilead. Paterson also reported receiving honoraria from Shionogi, Merck, GSK, bioMerieux, Cepheid, Aurobac, Arrepath, Menarini, CARB-X, and the AMR Action Fund. No other potential competing interest relevant to the letter was reported.
